Natural History of Asphyxiating Thoracic Dystrophy (DTJ) (DTJ)
Clinical and Molecular Study, Natural History of Asphyxiating Thoracic Dystrophy (DTJ)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Asphyxiating thoracic dysplasia (ATD, MIM 208500) belongs to the short rib polydactyly group and is characterized by short ribs often responsible for an early death due to respiratory distress, trident acetabular roof and short long bones.
In the course of the disease, renal, liver and eye complications may occur. However, their frequencies are unknown.
ATD is transmitted with an autosomal mode of inheritance and up till now only one gene has been identified, namely IFT80, which accounts only for a small part of ATD.
The aim of our project is to prospectively analyze at a clinical and molecular level a series of 50 ATD patients and 20 fetuses to further define the natural history of the disorder and to contribute to the identification of its molecular basis.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Hopital Necker
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with:
- Short ribs with narrow thorax
- Trident acetabular roof
- Short hands
Description
Inclusion Criteria:
- Short ribs with narrow thorax
- Trident acetabular roof
- Short hands
- All ages
- Informed consent signed
Exclusion Criteria:
- Other disease
- Ellis van creveld syndrome
- No social security
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients
All ages
|
Natural History
Other Names:
|
|
Fetuses
|
Natural History
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Natural history of asphyxiating thoracic dystrophy (ATD)
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Correlation Phenotype-Genotype
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Valérie Cormier-Daire, PUPH, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P060223
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asphyxiating Thoracic Dystrophy
-
NCT07038200RecruitingFacioscapulohumeral Muscular Dystrophy | FSHD | Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) | Facio-Scapulo-Humeral Dystrophy | FSHD - Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1
-
NCT07653971Not yet recruitingBietti's Crystalline Dystrophy | Bietti Crystalline Corneoretinal Dystrophy
-
NCT05747924CompletedMuscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy
-
NCT06547216Active, not recruitingMuscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy
-
NCT07409142RecruitingFacioscapulohumeral Muscular Dystrophy | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facioscapulohumeral Muscular Dystrophy (FSHD) | FSHD - Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | Facioscapulohumeral Muscular Dystrophy 2 | FSH Muscular Dystrophy
-
NCT07307469Enrolling by invitationBietti Crystalline Corneoretinal Dystrophy
-
NCT06881771RecruitingFuchs' Endothelial Dystrophy | Fuchs Dystrophy | Corneal Dystrophy | Fuchs' Endothelial Corneal Dystrophy of Bilateral Eyes | Corneal Dystrophy Fuchs
-
NCT01965041WithdrawnPattern Dystrophy of Macula
-
NCT00104078CompletedBecker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular Dystrophy
-
NCT01357122UnknownFuchs' Corneal Endothelial Dystrophy
Clinical Trials on IFT80 screening
-
NCT07482982CompletedFirearm Injury | Firearm Safety | Firearm Ownership
-
NCT03674307RecruitingCardiovascular Diseases | End Stage Renal Disease | Kidney Transplantation | Dialysis Related Complication
-
NCT01654991CompletedChlamydia | Gonorrhea
-
NCT05450094Enrolling by invitation
-
NCT03924609CompletedBreast Cancer | Bone Metastases
-
NCT05146609Recruiting
-
NCT04037046CompletedHepatitis C Virus Infection